Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13247614 | 0.88 | NAMPT (0.33) | NAMPT | |
| SCHEMBL9979410 | 0.85 | NAMPT (0.37) | NAMPTCA2 | |
| SCHEMBL11713000 | 0.84 | NAMPT (0.39) | NAMPTCA2 | |
| SCHEMBL9232549 | 0.84 | NAMPT (0.38) | NAMPTCA2 | |
| SCHEMBL3663814 | 0.83 | NAMPT (0.41) | NAMPTCA2 | |
| SCHEMBL3051827 | 0.83 | — | — | |
| SCHEMBL9238429 | 0.82 | NAMPT (0.38) | NAMPTCA2 | |
| SCHEMBL3663813 | 0.81 | NAMPT (0.40) | NAMPTCA2 | |
| SCHEMBL3026646 | 0.81 | LMNA (0.36) | — | |
| SCHEMBL9318639 | 0.80 | LMNA (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8323619-B2 | Contrast agents | GE HEALTHCARE AS (NO) | 2012-12-04 | — | — | US | disclosed |
| US-8323619-B2 | Contrast agents | GE HEALTHCARE AS (NO) | 2012-12-04 | — | — | US | disclosed |
| US-8202511-B2 | Contrast agents | GE HEALTHCARE AS (NO) | 2012-06-19 | — | — | US | disclosed |
| US-20100303734-A1 | CONTRAST AGENTS | GE HEALTHCARE AS (NO) | 2010-12-02 | — | — | US | disclosed |
| US-20100303734-A1 | CONTRAST AGENTS | GE HEALTHCARE AS (NO) | 2010-12-02 | — | — | US | disclosed |
| US-20100233097-A1 | CONTRAST AGENTS | GE HEALTHCARE AS (NO) | 2010-09-16 | — | — | US | disclosed |
| US-20100233097-A1 | CONTRAST AGENTS | GE HEALTHCARE AS (NO) | 2010-09-16 | — | — | US | disclosed |
| US-20100221192-A1 | CONTRAST AGENTS | GE HEALTHCARE AS (NO) | 2010-09-02 | — | — | US | disclosed |
| US-20100221192-A1 | CONTRAST AGENTS | GE HEALTHCARE AS (NO) | 2010-09-02 | — | — | US | disclosed |
| US-20100221189-A1 | CONTRAST AGENTS | GE HEALTHCARE AS (NO) | 2010-09-02 | — | — | US | disclosed |
| US-20100221189-A1 | CONTRAST AGENTS | GE HEALTHCARE AS (NO) | 2010-09-02 | — | — | US | disclosed |
| US-20100209356-A1 | CONTRAST AGENTS | GE HEALTHCARE AS (NO) | 2010-08-19 | — | — | US | disclosed |
| US-20100209356-A1 | CONTRAST AGENTS | GE HEALTHCARE AS (NO) | 2010-08-19 | — | — | US | disclosed |
| US-20100189656-A1 | CONTRAST AGENTS | GE HEALTHCARE AS (NO) | 2010-07-29 | — | — | US | disclosed |
| US-20100189656-A1 | CONTRAST AGENTS | GE HEALTHCARE AS (NO) | 2010-07-29 | — | — | US | disclosed |
| US-20100189656-A1 | CONTRAST AGENTS | GE HEALTHCARE AS (NO) | 2010-07-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100221189-A1 | CONTRAST AGENTS | NR1I3, NR1I2, NR1D2 | NAMPT 4271/4885CA2 2213/4885 |
| US-20100189656-A1 | CONTRAST AGENTS | IPO4, TPO, IPO11 | NAMPT 2709/4885CA2 1826/4885 |
| US-20100209356-A1 | CONTRAST AGENTS | C5, C1S, C1R | NAMPT 4169/4885CA2 843/4885 |
| US-20100221192-A1 | CONTRAST AGENTS | C5, C1S, C1R | NAMPT 3639/4885CA2 818/4885 |
| US-20100233097-A1 | CONTRAST AGENTS | C1R, C3AR1, CNKSR1 | NAMPT 4481/4885CA2 440/4885 |
| US-20100303734-A1 | CONTRAST AGENTS | C1R, CNKSR1, C5 | NAMPT 3758/4885CA2 494/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.